Jefferies (NYSE:JEF) analyst David Steinberg maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) on Tuesday, setting a price target of $220, which is approximately 21.21% above the present share price of $181.5.
Steinberg expects Jazz Pharmaceuticals to post earnings per share (EPS) of $2.16 for the third quarter of 2021.
The current consensus among 14 TipRanks analysts is for a Strong Buy rating of shares in Jazz Pharmaceuticals, with an average price target of $211.08.
The analysts price targets range from a high of $250 to a low of $176.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $607.58 million and a net profit of $162.12 million. The company's market cap is $11.02 billion.
According to TipRanks.com, Jefferies analyst David Steinberg is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 10.1% and a 52.92% success rate.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.